Portfolio Lab

10x Genomics, Inc.

  • Stock
  • Ticker TXG
  • ISIN US88025U1097
  • Nasdaq

Technology · Electronics and instruments · USA

$51.80 −9.72%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of 10x Genomics, Inc. since 09/2019, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

TXGGlobal equities (VT)

$10,000 grew to $3,212. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −96.5% in 04/2025, measured from the peak in 04/2021. The old peak has not been reached again yet.

1-year return
+214.7%
5-year return p.a.
−19.2%
Return p.a. since 09/2019
−0.3%
Volatility p.a.
64.2%
Largest decline
−96.5%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue165155173149166151151151
Gross profit111105125100113106112113
Operating income-50-3930-32-20-17-20-16
EBITDA-41-3138-22-9.5-7.1-9.9-6.6
Net income-49-3435-27-16-13-18-19
Earnings per share-0.41-0.280.28-0.22-0.13-0.10-0.14-0.15
Balance sheet
Total assets9199039801,0271,0411,0161,0301,063
Liabilities209196207242245201205225
Equity710707773785796814826838
Cash344377398433474490503526
Cash flow
Operating cash flow-6.734184341261716
Capital expenditure-2.7-1.9-1.6-0.7-1.8-1.6-1.6-1.0
Free cash flow-9.532164339251515

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2020 at +85.7%, weakest 2022 at −75.5%. 4 of 6 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
6 Nov 2026−$0.15
7 Aug 2026−$0.14
8 May 2026−$0.10
13 Feb 2026−$0.13
7 Nov 2025−$0.22
8 Aug 2025$0.28
9 May 2025−$0.28
13 Feb 2025−$0.41
29 Oct 2024−$0.30
8 Aug 2024−$0.32
30 Apr 2024−$0.50
15 Feb 2024−$0.41

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€6.1bn
Market cap in trading currency
$6.78bn
Enterprise value
$6.20bn
P/E
–
P/S
10.95
P/B
8.09
EV/Sales
10.02
EV/EBITDA
–
Earnings yield
–
FCF yield
1.4%

Results (last four quarters)

Revenue
$619m
Gross profit
$445m
EBITDA
−$33.0m
Net income
−$67.1m
Earnings per share
−$0.52
Revenue per share
$4.73
Revenue growth
+1.1%
Earnings growth
–

Profitability

Gross margin
71.9%
Operating margin
-11.7%
Net margin
-10.8%
Return on equity
-8.3%
Return on assets
-6.3%

Balance sheet and cash flow

Cash
$576m
Cash per share
$4.40
Financial debt
–
Debt/equity %
–
Current ratio
5.12
Book value per share
$6.41
Operating cash flow
$99.7m
Free cash flow
$93.8m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
131m
Volume
3.23m
Avg. volume 3 months
3.39m
Relative volume
1.0

Price and technicals

Price
$51.80
1 day
−9.7%
52-week high
$97.74
52-week low
$15.46
Distance to 52-week high
−47.0%
Distance to 52-week low
+235.1%
Distance to 50-day line
−28.9%
Distance to 200-day line
+19.1%
RSI (14)
35
Volatility 1M
112.7%

Performance

1 week
−11.0%
1 month
−25.7%
3 months
−18.8%
6 months
+118.8%
YTD
+217.6%
1 year
+231.0%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has TXG performed since 09/2019?

$10,000 grew to $9,820 by 20 Nov 2026, which is −0.3% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is TXG?

Volatility was 64.2% per year, measured on monthly returns. The largest decline from a peak was −96.5%, with the low in 04/2025.

How does TXG compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 16.4% volatility, TXG returned −0.3% at 64.2%. The correlation of monthly returns was 0.53; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

10x Genomics, Inc. (TXG): Return and risk | Portfolio Lab